201 related articles for article (PubMed ID: 29569125)
1. Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma.
Goense L; van Rossum PSN; Xi M; Maru DM; Carter BW; Meijer GJ; Ho L; van Hillegersberg R; Hofstetter WL; Lin SH
Ann Surg Oncol; 2018 Jun; 25(6):1598-1607. PubMed ID: 29569125
[TBL] [Abstract][Full Text] [Related]
2. Nomograms for predicting overall and recurrence-free survival after trimodality therapy for esophageal adenocarcinoma.
Merritt RE; Abdel-Rasoul M; Souza DM; Kneuertz PJ
J Surg Oncol; 2021 Mar; 123(4):881-890. PubMed ID: 33333590
[TBL] [Abstract][Full Text] [Related]
3. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
4. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer.
Hayashi Y; Xiao L; Suzuki A; Blum MA; Sabloff B; Taketa T; Maru DM; Welsh J; Lin SH; Weston B; Lee JH; Bhutani MS; Hofstetter WL; Swisher SG; Ajani JA
Eur J Cancer; 2012 Dec; 48(18):3396-404. PubMed ID: 22853875
[TBL] [Abstract][Full Text] [Related]
5. Validation of a Nomogram Predicting Survival After Trimodality Therapy for Esophageal Cancer.
Goense L; Merrell KW; Arnett AL; Hallemeier CL; Meijer GJ; Ruurda JP; Hofstetter WL; van Hillegersberg R; Lin SH
Ann Thorac Surg; 2018 Nov; 106(5):1541-1547. PubMed ID: 29932887
[TBL] [Abstract][Full Text] [Related]
6. Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience.
Sio TT; Wilson ZC; Stauder MC; Bhatia S; Martenson JA; Quevedo JF; Schomas DA; Miller RC
Am J Clin Oncol; 2016 Oct; 39(5):448-52. PubMed ID: 24879469
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?
Monjazeb AM; Riedlinger G; Aklilu M; Geisinger KR; Mishra G; Isom S; Clark P; Levine EA; Blackstock AW
J Clin Oncol; 2010 Nov; 28(31):4714-21. PubMed ID: 20876421
[TBL] [Abstract][Full Text] [Related]
8. Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.
Pucher PH; Rahman SA; Walker RC; Grace BL; Bateman A; Iveson T; Jackson A; Rees C; Byrne JP; Kelly JJ; Noble F; Underwood TJ
Eur J Surg Oncol; 2020 Dec; 46(12):2248-2256. PubMed ID: 32694054
[TBL] [Abstract][Full Text] [Related]
9. Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial.
Shimodaira Y; Slack RS; Harada K; Chen HC; Sagebiel T; Bhutani MS; Lee JH; Weston B; Elimova E; Lin Q; Amlashi FG; Mizrak Kaya D; Blum MA; Roth JA; Swisher SG; Skinner HD; Hofstetter WL; Rogers JE; Mares J; Thomas I; Maru DM; Komaki R; Walsh G; Ajani JA
Br J Cancer; 2018 Feb; 118(3):331-337. PubMed ID: 29235564
[TBL] [Abstract][Full Text] [Related]
10.
Xi M; Liao Z; Hofstetter WL; Komaki R; Ho L; Lin SH
J Nucl Med; 2017 Nov; 58(11):1756-1763. PubMed ID: 28522744
[TBL] [Abstract][Full Text] [Related]
11. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
[TBL] [Abstract][Full Text] [Related]
12. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.
Barbetta A; Hsu M; Tan KS; Stefanova D; Herman K; Adusumilli PS; Bains MS; Bott MJ; Isbell JM; Janjigian YY; Ku GY; Park BJ; Wu AJ; Jones DR; Molena D
J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2710-2721.e3. PubMed ID: 29548582
[TBL] [Abstract][Full Text] [Related]
13. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
[TBL] [Abstract][Full Text] [Related]
14. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
Nomura M; Oze I; Kodaira T; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Tachibana H; Uemura N; Tajika M; Niwa Y; Muto M; Muro K
Int J Clin Oncol; 2016 Oct; 21(5):890-898. PubMed ID: 26980212
[TBL] [Abstract][Full Text] [Related]
15. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
[TBL] [Abstract][Full Text] [Related]
16. The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy.
Kim GJ; Koshy M; Hanlon AL; Horiba MN; Edelman MJ; Burrows WM; Battafarano RJ; Suntharalingam M
Am J Clin Oncol; 2016 Apr; 39(2):136-41. PubMed ID: 24487417
[TBL] [Abstract][Full Text] [Related]
17. Patterns of recurrence after trimodality therapy for esophageal cancer.
Dorth JA; Pura JA; Palta M; Willett CG; Uronis HE; D'Amico TA; Czito BG
Cancer; 2014 Jul; 120(14):2099-105. PubMed ID: 24711267
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
Watanabe M; Baba Y; Yoshida N; Ishimoto T; Nagai Y; Iwatsuki M; Iwagami S; Baba H
Ann Surg Oncol; 2014 Sep; 21(9):2838-44. PubMed ID: 24715216
[TBL] [Abstract][Full Text] [Related]
19. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
